| NCT00317356 |
A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis |
PHASE2 |
TERMINATED |
Otsuka Pharmaceutical Co., Ltd. |
Colitis, Ulcerative |
DRUG: OPC-6535(Tetomilast) |
Details |
| NCT00064454 |
FACTS II: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis |
PHASE3 |
COMPLETED |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
Ulcerative Colitis |
DRUG: OPC-6535 Tablets (drug) |
Details |
| NCT00064441 |
FACTS I: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis |
PHASE3 |
COMPLETED |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
Ulcerative Colitis |
DRUG: OPC-6535 Tablets (drug) |
Details |
| NCT00092508 |
CORE: A Study of OPC-6535 With Asacol in Maintaining Ulcerative Colitis (UC) Remission |
PHASE3 |
COMPLETED |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
Ulcerative Colitis |
DRUG: OPC-6535|DRUG: Asacol |
Details |
| CTIS2023-508224-35-01 |
Analgesic effect of intravenous lidocaine and its mechanisms in patients suffering from chronic inflammatory bowel disease (IBD) with abdominal pain. |
PHASE2 |
Recruiting |
CHU De Liege |
Inflammatory Bowel disease;Therapeutic area: Dise… |
Product Name: Linisol 1 %, solution injectable, P… |
Details |
| CTIS2023-508584-72-00 |
Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous as Induction Therapy in Patients with Active Crohn's Disease or Ulcerative Colitis - 2023/12 |
PHASE3 |
Not Recruiting |
Centre Medico Chirurgical Ambroise Pare Hartmann |
Immune Bowel Disease (including Crohn's disease a… |
Product Name: Remsima 100 mg powder for concentra… |
Details |
| NCT04624230 |
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis |
PHASE3 |
RECRUITING |
Pfizer |
Ulcerative Colitis |
DRUG: tofacitinib |
Details |
| NCT06651281 |
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) |
PHASE3 |
RECRUITING |
Merck Sharp & Dohme LLC |
Crohn Disease|Colitis, Ulcerative |
DRUG: Tulisokibart|DRUG: Placebo to tulisokibart |
Details |
| NCT04985968 |
The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis |
PHASE3 |
TERMINATED |
InDex Pharmaceuticals |
Ulcerative Colitis |
DRUG: Cobitolimod 250 mg|DRUG: Cobitolimod 500 mg… |
Details |
| NCT06681181 |
A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK4528287 in Healthy Participants |
PHASE1 |
RECRUITING |
GlaxoSmithKline |
Colitis, Ulcerative |
DRUG: GSK4528287|DRUG: Placebo |
Details |
| NCT06353828 |
Phase 2a Study to Evaluate IcBD-01 Enema in Active Ulcerative Colitis Patients |
PHASE2 |
ACTIVE_NOT_RECRUITING |
CannaMore Biotechs |
Ulcerative Colitis |
DRUG: CBD, synthetic form|DRUG: Placebo |
Details |
| NCT06321887 |
EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD |
PHASE3 |
RECRUITING |
Liverpool University Hospitals NHS Foundation Trust |
Inflammatory Bowel Disease|Iron Deficiency Anemia |
DRUG: Ferrous fumarate syrup 2.5ml/70mg (22.5mg e… |
Details |
| NCT01011322 |
A Study to Investigate the Efficacy of LT-02 in Patients With Mesalazine Refractory Ulcerative Colitis |
PHASE2 |
UNKNOWN |
Lipid Therapeutics GmbH |
Ulcerative Colitis|Large Intestine|Diarrhea|Abdom… |
DRUG: LT-02|DRUG: placebo |
Details |
| NCT02610569 |
Comparison of PillCamCOLON (C2) Capsule and Standard Endoscopy for the Evaluation of Patients With Ulcerative Colitis |
None |
COMPLETED |
Dr. Arnaud Bourreille |
Ulcerative Colitis |
DEVICE: standard endoscopy|DEVICE: PillCamCOLON (… |
Details |
| NCT06109441 |
Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics |
PHASE2 |
RECRUITING |
AltruBio Inc. |
Ulcerative Colitis |
BIOLOGICAL: ALTB-268 |
Details |
| NCT06420492 |
Study of Novel Therapeutics for Acute Remedy of Colitis |
PHASE2 |
NOT_YET_RECRUITING |
Brigham and Women's Hospital |
Ulcerative Colitis|Ulcerative Colitis Chronic Mod… |
DRUG: BRS201 |
Details |
| NCT02039505 |
Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis |
PHASE3 |
COMPLETED |
Takeda |
Ulcerative Colitis |
DRUG: Vedolizumab|DRUG: Vedolizumab placebo |
Details |
| NCT02392221 |
Impact of Therapeutic Strategies in the Pediatric Inflammatory Bowel Disease: a Population Based Study (1988-2011). |
None |
COMPLETED |
Centre Hospitalier Universitaire, Amiens |
Pediatric Inflammatory Bowel Disease |
None |
Details |
| NCT05907330 |
Phase 2 Study of CU104 in Moderate-Severe Ulcerative Colitis |
PHASE2 |
NOT_YET_RECRUITING |
Curacle Co., Ltd. |
Ulcerative Colitis |
DRUG: CU104|DRUG: Placebo |
Details |
| NCT01100112 |
(CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets |
PHASE3 |
COMPLETED |
Bausch Health Americas, Inc. |
Colitis, Ulcerative |
DRUG: Budesonide |
Details |
